The tuberous sclerosis complex (TSC)2 gene regulates the mammalian target of rapamycin (mTOR) pathway, impacting cell proliferation and growth. The loss-of-function mutations, especially in mesenchymal progenitors, drive the development multiple benign and malignant tumors. TSC2 mutations in certain cancer types, e.g., breast cancer, are also associated with poorer prognosis. The databases of TSC2-mutations report point mutations as the most prevalent. We aimed to test the feasibility of inducing point mutations in mesenchymal stem cells (MSCs), targeting the most frequent point mutations of the TSC2 gene, TSC2. c.1864 C>T (p.Arg622Trp), TSC2. c.1832 G>A (p.Arg611Glu), and TSC2. c.5024 C>T (p.Pro1675Leu) using two delivery methods for CRISPR-Cas9. We report a high editing efficiency of up to 85% inducing TSC2 point mutations in hMSCs using lipofectamine-based transfection. Overall, the high editing efficiency of some TSC2 mutations enables the induction and reversal of mutations in primary hMSCs without needing resource-consuming derivation of cell lines frequently distinct from their primary counterparts.
Get full access to this article
View all access options for this article.
References
1.
BisslerJJ, McCormackFX, YoungLR, et al.Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med, 2008; 358(2):140–151; doi: 10.1056/NEJMoa063564
2.
CuratoloP, MoaveroR, van ScheppingenJ, et al.mTOR dysregulation and tuberous sclerosis-related epilepsy. Expert Rev Neurother, 2018; 18(3):185–201; doi: 10.1080/14737175.2018.1428562
3.
KwiatkowskiDJ. Tuberous sclerosis: From tubers to mTOR. Ann Hum Genet, 2003; 67(Pt 1):87–96; doi: 10.1046/j.1469-1809.2003.00012.x
4.
CabanC, KhanN, HasbaniDM, et al.Genetics of tuberous sclerosis complex: Implications for clinical practice. Appl Clin Genet, 2017; 10:1–8; doi: 10.2147/TACG.S90262
5.
DibbleCC, CantleyLC. Regulation of mTORC1 by PI3K signaling. Trends Cell Biol, 2015; 25(9):545–555; doi: 10.1016/j.tcb.2015.06.002
KurianAW, WardKC, AbrahamseP, et al.Time trends in receipt of germline genetic testing and results for women diagnosed with breast cancer or ovarian cancer, 2012-2019. J Clin Oncol, 2021; 39(15):1631–1640; doi: 10.1200/JCO.20.02785
8.
YeQ, LingS, JiangG, et al.Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria. Eur J Surg Oncol, 2021; 47(10):2533–2542; doi: 10.1016/j.ejso.2021.04.001
9.
LiangMC, MaJ, ChenL, et al.TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene, 2010; 29(11):1588–1597; doi: 10.1038/onc.2009.452
10.
MehtaMS, VazquezA, KulkarniDA, et al.Polymorphic variants in TSC1 and TSC2 and their association with breast cancer phenotypes. Breast Cancer Res Treat, 2011; 125(3):861–868; doi: 10.1007/s10549-010-1062-1
11.
WangS, ZhangC, XuZ, et al.Differential impact of PI3K/AKT/mTOR signaling on tumor initiation and progression in animal models of prostate cancer. Prostate, 2023; 83(1):97–108; doi: 10.1002/pros.24441
12.
ChakrabortyS, MohiyuddinSM, GopinathKS, et al.Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC Cancer, 2008; 8:163; doi: 10.1186/1471-2407-8-163
13.
JiangWG, SampsonJ, MartinTA, et al.Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: The role of promoter methylation of TSC genes. Eur J Cancer, 2005; 41(11):1628–1636; doi: 10.1016/j.ejca.2005.03.023
14.
SridharanS, BasuA. Distinct roles of mTOR Targets S6K1 and S6K2 in breast cancer. Int J Mol Sci, 2020; 21(4):1199; doi: 10.3390/ijms21041199
15.
MaskeyRS, WangF, LehmanE, et al.Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells. Cell Cycle, 2021; 20(1):65–80; doi: 10.1080/15384101.2020.1859195
16.
MiricescuD, TotanA, StanescuSII, et al.PI3K/AKT/mTOR signaling pathway in breast cancer: From molecular landscape to clinical aspects. Int J Mol Sci, 2020; 22(1):173; doi: 10.3390/ijms22010173
17.
NellistM, BrouwerRW, KockxCE, et al.Targeted next generation sequencing reveals previously unidentified TSC1 and TSC2 mutations. BMC Med Genet, 2015; 16:10; doi: 10.1186/s12881-015-0155-4
18.
NorthrupH, KruegerDA, International Tuberous Sclerosis Complex Consensus G. Tuberous sclerosis complex diagnostic criteria update: Recommendations of the 2012 Iinternational Tuberous sclerosis complex consensus conference. Pediatr Neurol, 2013; 49(4):243–254; doi: 10.1016/j.pediatrneurol.2013.08.001
19.
Wataya-KanedaM, UemuraM, FujitaK, et al.; Tuberous Sclerosis Complex Board of Osaka University Hospital. Tuberous sclerosis complex: Recent advances in manifestations and therapy. Int J Urol, 2017; 24(9):681–691; doi: 10.1111/iju.13390
20.
WangX, ZhaoY, WangZ, et al.Construction of TSC2 knockout cell line using CRISPR/Cas9 system and demonstration of its effects on NIH-3T3 cells. Cell Biochem Biophys, 2022; 80(4):681–687; doi: 10.1007/s12013-022-01094-0
21.
KloverPJ, ThangapazhamRL, KatoJ, et al.Tsc2 disruption in mesenchymal progenitors results in tumors with vascular anomalies overexpressing Lgals3. Elife, 2017; 6:e23202; doi: 10.7554/eLife.23202
22.
CuratoloP, NabboutR, LagaeL, et al.Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations. Eur J Paediatr Neurol, 2018; 22(5):738–748; doi: 10.1016/j.ejpn.2018.05.006
23.
SadowskiK, SijkoK, Domańska-PakiełaD, et al.Antiepileptic effect and safety profile of rapamycin in pediatric patients with tuberous sclerosis complex. Front Neurol, 2022; 13:704978; doi: 10.3389/fneur.2022.704978
24.
SadowskiK, KotulskaK, JóźwiakS. Management of side effects of mTOR inhibitors in tuberous sclerosis patients. Pharmacol Rep, 2016; 68(3):536–542; doi: 10.1016/j.pharep.2016.01.005
25.
NabboutR, BelousovaE, BenedikMP, et al.; TOSCA Consortium and TOSCA Investigators. Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study. Epilepsia Open, 2019; 4(1):73–84; doi: 10.1002/epi4.12286
26.
UysalSP, ŞahinM. Tuberous sclerosis: A review of the past, present, and future. Turk J Med Sci, 2020; 50(SI-2):1665–1676; doi: 10.3906/sag-2002-133
27.
SłowińskaM, JóźwiakS, PeronA, et al.Early diagnosis of tuberous sclerosis complex: A race against time. How to make the diagnosis before seizures? Orphanet J Rare Dis, 2018; 13(1):25; doi: 10.1186/s13023-018-0764-z
28.
Gornicka-PawlakE, JanowskiM, HabichA, et al.Intra-arterial administration of human umbilical cord blood derived cells inversed learning asymmetry resulting from focal brain injury in rat. Front Neurol, 2019; 10:786; doi: 10.3389/fneur.2019.00786
29.
ZhangS, FanJ, SunH, et al.Generation of a TSC2 knockout embryonic stem cell line by CRISPR/Cas9 editing. Stem Cell Res, 2024; 77:103399; doi: 10.1016/j.scr.2024.103399
30.
FajrialAK, HeQQ, WirusantiNI, et al.A review of emerging physical transfection methods for CRISPR/Cas9-mediated gene editing. Theranostics, 2020; 10(12):5532–5549; doi: 10.7150/thno.43465
31.
ChongZX, YeapSK, HoWY. Transfection types, methods and strategies: A technical review. PeerJ, 2021; 9:e11165; doi: 10.7717/peerj.11165
32.
Mohammadian FarsaniA, MokhtariN, NooraeiS, et al.Lipid nanoparticles: The game-changer in CRISPR-Cas9 genome editing. Heliyon, 2024; 10(2):e24606; doi: 10.1016/j.heliyon.2024.e24606
33.
NowakowskiA, AndrzejewskaA, BoltzeJ, et al.Translation, but not transfection limits clinically relevant, exogenous mRNA based induction of alpha-4 integrin expression on human mesenchymal stem cells. Sci Rep, 2017; 7(1):1103; doi: 10.1038/s41598-017-01304-3
34.
AndrzejewskaA, GrzelaR, Stankiewicz-DrogonA, et al.Mesenchymal stem cell engineering by ARCA analog-capped mRNA. Mol Ther Nucleic Acids, 2023; 33:454–468; doi: 10.1016/j.omtn.2023.07.006
35.
JanowskiM, LyczekA, EngelsC, et al.Cell size and velocity of injection are major determinants of the safety of intracarotid stem cell transplantation. J Cereb Blood Flow Metab, 2013; 33(6):921–927; doi: 10.1038/jcbfm.2013.32
36.
AndrzejewskaA, DabrowskaS, NowakB, et al.Mesenchymal stem cells injected into carotid artery to target focal brain injury home to perivascular space. Theranostics, 2020; 10(15):6615–6628; doi: 10.7150/thno.43169
37.
SarmahD, DattaA, RanaN, et al.SIRT-1/RHOT-1/PGC-1alpha loop modulates mitochondrial biogenesis and transfer to offer resilience following endovascular stem cell therapy in ischemic stroke. Free Radic Biol Med, 2024; 225:255–274; doi: 10.1016/j.freeradbiomed.2024.09.022
38.
KantorA, McClementsME, MacLarenRE. CRISPR-Cas9 DNA Base-editing and prime-editing. Int J Mol Sci, 2020; 21(17):6240; doi: 10.3390/ijms21176240
39.
AnzaloneAV, KoblanLW, LiuDR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol, 2020; 38(7):824–844; doi: 10.1038/s41587-020-0561-9
40.
CerisolaA, CibilsL, ChaibunME, et al.Tuberous sclerosis complex: Diagnosis and current treatment. Medicina (B Aires), 2022; 82 Suppl 3:71–75.
41.
MatanoM, DateS, ShimokawaM, et al.Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids. Nat Med, 2015; 21(3):256–262; doi: 10.1038/nm.3802
42.
FesslerE, DrostJ, van HooffSR, et al.TGFbeta signaling directs serrated adenomas to the mesenchymal colorectal cancer subtype. EMBO Mol Med, 2016; 8(7):745–760; doi: 10.15252/emmm.201606184
43.
Morshedi RadD, Alsadat RadM, Razavi BazazS, et al.A comprehensive review on intracellular delivery. Adv Mater, 2021; 33(13):e2005363; doi: 10.1002/adma.202005363
44.
MunJY, ShinKK, KwonO, et al.Minicircle microporation-based non-viral gene delivery improved the targeting of mesenchymal stem cells to an injury site. Biomaterials, 2016; 101:310–320; doi: 10.1016/j.biomaterials.2016.05.057
45.
MadeiraC, RibeiroSC, PinheiroIS, et al.Gene delivery to human bone marrow mesenchymal stem cells by microporation. J Biotechnol, 2011; 151(1):130–136; doi: 10.1016/j.jbiotec.2010.11.002
46.
GuoG, MoserM, ChifambaL, et al.CRISPR-Cas9-mediated correction of TSC2 pathogenic variants in iPSCs from patients with Tuberous Sclerosis Complex Type 2. CRISPR J, 2025; 8(1):60–70; doi: 10.1089/crispr.2024.0079
47.
Abdul HalimNS, FakiruddinKS, AliSA, et al.A comparative study of non-viral gene delivery techniques to human adipose-derived mesenchymal stem cell. Int J Mol Sci, 2014; 15(9):15044–15060; doi: 10.3390/ijms150915044
48.
YuX, LiangX, XieH, et al.Improved delivery of Cas9 protein/gRNA complexes using lipofectamine CRISPRMAX. Biotechnol Lett, 2016; 38(6):919–929; doi: 10.1007/s10529-016-2064-9
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
